SCHEMBL26976556

SCHEMBL26976556

CC(C)(C)c1cc(C(=O)O)n(C2COC2)n1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GRN P28799 8/20 0.54
▸ SORT1 Q99523 8/20 0.54
▸ KDM4E B2RXH2 1/20 0.54
▸ NPC1 O15118 1/20 0.40
▸ MAPK13 O15264 1/20 0.39
▸ MAPK12 P53778 1/20 0.39
▸ MAPK11 Q15759 1/20 0.39
▸ MAPK14 Q16539 1/20 0.39
▸ MEN1 O00255 1/20 0.34
▸ KMT2A Q03164 1/20 0.34
▸ CNR1 P21554 2/20 0.33
▸ CNR2 P34972 2/20 0.33
▸ GALR3 O60755 2/20 0.33
▸ AURKA O14965 1/20 0.33
▸ CSF1R P07333 1/20 0.33
▸ RET P07949 1/20 0.33
▸ LTK P29376 1/20 0.33
▸ CSNK1A1 P48729 1/20 0.33
▸ CDK8 P49336 1/20 0.33
▸ CLK2 P49760 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26976513 0.86 GRN (0.58) GRNSORT1KDM4ENPC1MAPK13
SCHEMBL26976574 0.81 GRN (0.38) GRNSORT1KDM4EMEN1KMT2A
SCHEMBL30559528 0.73 CDK8 (0.47) GRNSORT1KDM4ENPC1MAPK13
SCHEMBL22637140 0.71 KLKB1 (0.44) GRNSORT1KDM4EMAPK13MAPK12
SCHEMBL1572486 0.71 GRN (1.00) GRNSORT1KDM4ENPC1MAPK13
SCHEMBL3761678 0.71 GRN (0.58) GRNSORT1KDM4ENPC1MAPK14
Hydrochloric Acid SCHEMBL8760885 0.69 GRN (0.96) GRNSORT1KDM4ENPC1MAPK13
SCHEMBL3186489 0.69 GRN (0.56) GRNSORT1KDM4ENPC1MAPK14
SCHEMBL26976579 0.68 KMT2A (0.40) GRNSORT1KDM4EMAPK13MAPK12
SCHEMBL950587 0.68 NR3C2 (0.46) GRNSORT1KDM4EMAPK13MAPK12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4619388-A1 CATHEPSIN L INHIBITORS Biofront Therapeutics (Beijing) Co., Ltd. (CN) 2025-09-24 — — EP disclosed
WO-2024140356-A1 CATHEPSIN L INHIBITORS BIOFRONT THERAPEUTICS (BEIJING) CO., LTD. (CN) 2024-07-04 — — WO disclosed
US-11858905-B1 Cathepsin L inhibitors BIOFRONT THERAPEUTICS (BEIJING) CO., LTD. (CN) 2024-01-02 — — US disclosed
CN-116589425-A Cathepsin L inhibitors 百放英库医药科技(北京)有限公司 2023-08-15 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11858905-B1 Cathepsin L inhibitors CTSV, CTSL, CTSB GRN 816/4885SORT1 616/4885KDM4E 4319/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback